Maynard Um
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene (CLNN) Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene, Inc. (CLNN) PT Lowered to $83 at Canaccord Genuity
-
-
-
-
-
-
-
EF Hutton Starts Clene, Inc. (CLNN) at Buy
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

